The global painkillers market is expected to enjoy a valuation of US$ 70.0 Billion by the end of the year 2023, and further expand at a CAGR of 3.7% to reach a valuation of ~US$ 100.9 Billion by the year 2033. According to a recent study by Future Market Insights, opioids are leading the market with a share of about 53.4% in the year 2022, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 67.7 Billion |
| Market Value 2023 | US$ 70.0 Billion |
| Market Value 2033 | US$ 100.9 Billion |
| CAGR 2023 to 2032 | 3.7% |
| Market Share of Top 5 Countries (2022) | 59.1% |
| Key Market Players | AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., Boehringer Ingelheim International GmbH, Pfizer Inc., Zydus Lifesciences Ltd. (Cadila Pharmaceuticals), GSK plc., Abbott Laboratories, Inc., Novartis AG, Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Ltd., Mallinckrodt Pharmaceuticals, Endo Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Procter & Gamble, AstraZeneca, Cardinal Health, Perrigo Company Plc., Bausch Health Companies Inc., Viatris, Amneal Pharmaceuticals, and Purdue Pharmaceuticals L.P. |
Manufacturers are focused on developing non-opioid drugs with a novel extended-release delivery approach that can relieve postoperative pain over a longer period of time. Opioid drugs are highly effective pain relievers, but they are also highly addictive and can lead to abuse and dependence. The opioid epidemic has led to a growing need for non-opioid pain management options.
Overall, the development of non-opioid extended-release pain medications is an important step in addressing the opioid epidemic and providing patients with a safer option, thereby will drive the overall growth of the painkillers market during the forecast period (2023 to 2033).
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for painkillers was around 4.8% of the overall ~US$ 1,400.5 Billion of the global pharmaceuticals market in 2022.
An increasing number of patients suffering from chronic diseases such as cancer and chronic obstructive pulmonary disease (COPD), various prescription drugs for postoperative pain management, and various traumas leading to pain are expected to fuel the growth of global market for painkillers.
Certain health conditions such as diabetes, cancer, and autoimmune diseases are known to increase the risk of developing chronic pain and neuropathic pain. Therefore, it is important that healthcare providers are aware of the increasing prevalence of these conditions and provide appropriate treatment strategies to improve patients’ quality of life.
Overall, the global market is projected to expand at a CAGR of 3.7% during the forecast period (2023 to 2033).
The regulatory scenario for painkillers can have a significant impact on the growth of the market. In recent years, opioid pain medications have come under increased scrutiny, resulting in stricter regulations and restrictions on their use. This has created opportunities for non-opioid pain medications such as NSAIDs and other non-narcotic medications to gain market share. In addition, regulatory initiatives to improve pain management and reduce opioid abuse, such as prescription drug monitoring programs and physician education programs, may create opportunities for companies offering alternative pain management solutions.
Overall, the regulatory scenario for painkillers is complex and evolving. However, regulatory initiatives that promote safe and effective pain management can create growth opportunities for the painkillers manufacturers, especially for companies that offer innovative solutions.
The companies that navigate the regulatory landscape and invest in innovative solutions to meet the evolving needs of patients and healthcare providers offer lucrative growth opportunities for the market and will raise the market to new heights during the forecast period from 2023 to 2033.
Principal Consultant
Per capita use of opioids is low in Asian countries. According to the Global Opioids Policy Initiative (GOPI), some of the main factors responsible for low opioid use in Asia and Africa include: full patient cost coverage is required, patient registration required before prescribing opioids, and physicians must obtain special permission to prescribe opioids.
The availability of painkillers in Asian and African countries may have a significant impact on the growth of the painkiller market in these regions. In many of these countries, access to painkillers is limited due to various factors such as lack of infrastructure, regulatory issues, and economic constraints. This can lead to a significant unmet need for painkillers, which can ultimately impact the growth of the market.
These factors are negatively impacting the growth of the painkillers market in Asia and Africa and projections have been made which are restraining the growth of the market during the forecast period from 2023 to 2033 in the world.
With a market share of 91.5% in 2022, the USA will continue to dominate the North American region. This large market share is expected to continue throughout the forecast period.
In the USA, palliative care facilities are provided in accordance with government and commercial reimbursement guidelines. Palliative care programs in hospitals in the USA include dedicated inpatient palliative care units and palliative care consultation teams.
Also, the American Chronic Pain Association has designated September as Pain Awareness Month, and more than 80 organizations and healthcare professionals, and consumer groups have supported the initiative. This will result in the propulsion of demand for painkillers in the country during the forecast period of 2023 to 2033.
Germany dominates the Western European region with a total market share of about 25.6% in 2022 and is expected to continue to experience the same growth throughout the forecast period.
In Germany, there is a growing interest in personalized medicine, which is also reflected in the painkillers market. Pharmaceutical companies are developing painkillers tailored to specific patient groups, such as the elderly or people with kidney problems, in order to achieve more targeted and effective pain relief. This will foster profitable market growth over the course of the forecast period.
Japan dominates the East Asia region with market share of 45.1% in 2022 and will expand with growing numbers in the future.
Japan has taken various initiatives to improve pain management, including the establishment of pain clinics, the development of clinical guidelines for pain management, and the training of healthcare professionals in pain management.
The Japan market for painkillers is expected to continue to grow in the coming years, driven by changing demographics, shifting consumer preferences, and increasing investment in pain management R&D all suggest that Japan will continue to be an important market for painkillers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Opioids are expected to present growth at a CAGR of 2.1% throughout the forecast period, with a market share of 53.4% in the global market in 2022.
Opioids are relatively inexpensive compared to some of the newer non-opioid pain medications. Opioids have been used for pain relief for centuries, and many healthcare providers are familiar with their use and feel comfortable prescribing them.
As the demand for non-opioids continues to grow, the market for painkillers is expected to expand significantly in the coming years.
Prescription Drugs dominated the global market with a value share of 58.8% in 2022.
Prescription drugs are leading in the global market for painkillers over over-the-counter (OTC) drugs because they are often more effective at providing pain relief for moderate to severe pain. Prescription painkillers are also often covered by health insurance, which can make them more affordable for patients who need them.
Surgical pain is leading the market with a market share of 43.3% in the global market in 2022.
Surgical pain is leading in the market over other indications because surgery is a common cause of acute pain, and pain relief is an important part of the post-surgical recovery process. Many surgical procedures can be painful, and without adequate pain control, patients may experience significant discomfort, which can delay healing and recovery.
The oral route of administration is leading the market with a revenue share of 38.7% in 2022 as oral painkillers are easy to take and can be self-administered, which can make them more convenient for patients and also it is generally less invasive than other routes, such as injections or transdermal patches, which can make it more appealing for patients.
Retail pharmacies hold a market share value of 27.5% during the year 2022. Retail pharmacies typically stock a wide range of painkillers, including both prescription and over-the-counter options and they are easily accessible to consumers, which makes it convenient for them to purchase painkillers.
Key market players in the painkillers market launch their products. This promotional strategy is expected to be highly impactful to enter into the market.
A few of the recent instances include
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the Painkillers market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Western Europe, Eastern Europe, Russia & Belarus, Balkan & Baltic Countries, South Asia & Pacific, East Asia, Central Asia, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Spain, France, BENELUX, Nordic Countries, Poland, Hungary, Czech Republic, Romania, Russia and Belarus, Balkan & Baltic Countries, India, Thailand, Indonesia, Malaysia, Vietnam, Philippines, Japan, China, South Korea, Central Asia, Australia and New Zealand, Türkiye, GCC Countries, Kingdom of Saudi Arabia, Israel, North Africa, and South Africa |
| Key Market Segments Covered | Drug Class, Product, Indication, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled |
|
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The painkillers market is expected to reach a valuation of at US$ 70.0 billion in 2023.
AbbVie Inc. (Allergan plc), Bristol Myers Squibb Co., Sanofi S.A., are leading painkillers industry players.
Opioids are the key segment by drug class in the worldwide painkillers market.
Over the historical period, from 2018 to 2022, the painkillers market registered a 2.9% CAGR.
North America painkillers market is expected to hold a 92.2% share in 2023.
1. Executive Summary | Painkillers Market 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Patient Treatment Journey 4.2. Disease Epidemiology 4.3. Standard daily doses per 100,000 people, By Countries 4.4. Trends in Use of Prescription Opioids 4.5. Annual Mean Consumption of Controlled Opioids 4.6. Changes in Drug Overdose Deaths in USA, 2019 to 2020 4.7. Overdose Death Rates Involving Opioids, By Type, USA, 1999 to 2020 4.8. Total Opioid Prescriptions Dispensed and Opioid Dispensing Rate per 100 People 4.9. Number of Prescription, By Drug Class, Indication and Route of Administration 4.10. Commercial Scope of Opioids and Abuse Deterrent Technologies (ADT) 4.11. Approved Extended-release and Long-acting (ER/LA) Opioids with Abuse-deterrent Properties 4.12. Abuse Deterrent Opioid Formulation Status 4.13. Top 20 most commonly used NSAIDs 4.14. Percentage of Individual NSAID Usage and Prescription of NSAIDs by Different Indications 4.15. Pipeline Assessment 4.15.1. By Drug Class 4.15.2. Comprehensive Assessment by Phases 4.15.3. Emerging Novel trends 4.15.4. Late-stage Pipeline Drugs Assessment 4.16. List of Key Players, By Region 4.17. Key Regulations 4.18. Reimbursement Landscape 4.19. PESTLE Analysis 4.20. Porter’s Analysis 4.21. Value chain analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Growth Outlook 5.1.2. Global Healthcare Expenditure Outlook 5.1.3. Global Life Expectancy Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Top Companies Historical Growth 5.2.2. Increasing Treatment Seeking Rate 5.2.3. Healthcare Bodies Advocating Adoption of Combat Methodological Approach 5.2.4. Increasing Aging Population 5.2.5. Patent Expiration of Novel Pain Management Drugs (Opioids) 5.2.6. Introduction of Novel Abuse-deterrent Pain Management Drugs 5.2.7. Average Annual Spending on Pain Management Drugs 5.2.8. Awareness for Pain Management Drugs 5.2.9. Popularity of Generic Products 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-19 Crisis Analysis 6.1. Current COVID-19 Statistics and Probable Future Impact 6.2. COVID-19 and Impact Analysis 6.2.1. By Drug Class 6.2.2. By Product 6.2.3. By Indication 6.2.4. By Route of Administration 6.2.5. By Distribution Channel 7. Global Market Demand (in Value or Size in US$ Million) Analysis 2018 to 2022 and Forecast, 2023 to 2033 7.1. Historical Market Value (US$ Million) Analysis 2018 to2022 7.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2018 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 8.3.1. Opioids 8.3.1.1. Tramadol 8.3.1.2. Oxycodone 8.3.1.3. Hydrocodone 8.3.1.4. Other Opioids 8.3.2. NSAIDs 8.3.3. Local Anesthetics 8.3.4. Acetaminophen 8.4. Market Attractiveness Analysis By Drug Class 9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Analysis By Product, 2018 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Over-The-Counter (OTC) Products 9.3.2. Prescription Drugs 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Indication, 2018 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 10.3.1. Surgical Pain 10.3.2. Cancer Pain 10.3.3. Neuropathic Pain 10.3.4. Musculoskeletal & Joint Pain 10.3.5. Others 10.4. Market Attractiveness Analysis By Indication 11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2018 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 11.3.1. Injectable 11.3.2. Oral 11.3.3. Rectal 11.3.4. Topical 11.3.5. Transdermal 11.3.6. Others 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Distribution Channel , 2018 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 12.3.1. Hospital Pharmacies 12.3.2. Specialty Clinics 12.3.3. Long Term Care Centers 12.3.4. Retail pharmacies 12.3.5. Drug Stores 12.3.6. Online Pharmacies 12.4. Market Attractiveness Analysis By Distribution Channel 13. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, by Region 13.1. Introduction Historical Market Size (US$ Million) Analysis By Region, 2018 to 2022 13.2. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 13.2.1. North America 13.2.2. Latin America 13.2.3. Western Europe 13.2.4. Eastern Europe 13.2.5. Russia & Belarus 13.2.6. Balkan & Baltic Countries 13.2.7. South Asia & Pacific 13.2.8. East Asia 13.2.9. Central Asia 13.2.10. Middle East & Africa 13.3. Market Attractiveness Analysis By Region 14. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. USA 14.3.1.2. Canada 14.3.2. By Drug Class 14.3.3. By Product 14.3.4. By Indication 14.3.5. By Route of Administration 14.3.6. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Class 14.4.3. By Product 14.4.4. By Indication 14.4.5. By Route of Administration 14.4.6. By Distribution Channel 14.5. Market Trends 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. USA Market 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Drug Class 14.7.1.2.2. By Product 14.7.1.2.3. By Indication 14.7.1.2.4. By Route of Administration 14.7.1.2.5. By Distribution Channel 14.7.2. Canada Market 14.7.3. Introduction 14.7.4. Market Analysis and Forecast by Market Taxonomy 14.7.4.1.1. By Drug Class 14.7.4.1.2. By Product 14.7.4.1.3. By Indication 14.7.4.1.4. By Route of Administration 14.7.4.1.5. By Distribution Channel 15. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. Brazil 15.3.1.2. Mexico 15.3.1.3. Argentina 15.3.1.4. Rest of Latin America 15.3.2. By Drug Class 15.3.3. By Product 15.3.4. By Indication 15.3.5. By Route of Administration 15.3.6. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Class 15.4.3. By Product 15.4.4. By Indication 15.4.5. By Route of Administration 15.4.6. By Distribution Channel 15.5. Market Trends 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Brazil Market 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Drug Class 15.7.1.2.2. By Product 15.7.1.2.3. By Indication 15.7.1.2.4. By Route of Administration 15.7.1.2.5. By Distribution Channel 15.7.2. Mexico Market 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Drug Class 15.7.2.2.2. By Product 15.7.2.2.3. By Indication 15.7.2.2.4. By Route of Administration 15.7.2.2.5. By Distribution Channel 15.7.3. Argentina Market 15.7.4. Introduction 15.7.5. Market Analysis and Forecast by Market Taxonomy 15.7.5.1.1. By Drug Class 15.7.5.1.2. By Product 15.7.5.1.3. By Indication 15.7.5.1.4. By Route of Administration 15.7.5.1.5. By Distribution Channel 16. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Germany 16.3.1.2. France 16.3.1.3. Spain 16.3.1.4. Italy 16.3.1.5. BENELUX 16.3.1.6. Nordic Countries 16.3.1.7. United kingdom 16.3.2. By Drug Class 16.3.3. By Product 16.3.4. By Indication 16.3.5. By Route of Administration 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Product 16.4.4. By Indication 16.4.5. By Route of Administration 16.4.6. By Distribution Channel 16.5. Market Trends 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. Germany Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Drug Class 16.7.1.2.2. By Product 16.7.1.2.3. By Indication 16.7.1.2.4. By Route of Administration 16.7.1.2.5. By Distribution Channel 16.7.2. France Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Drug Class 16.7.2.2.2. By Product 16.7.2.2.3. By Indication 16.7.2.2.4. By Route of Administration 16.7.2.2.5. By Distribution Channel 16.7.3. Spain Market 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Drug Class 16.7.3.2.2. By Product 16.7.3.2.3. By Indication 16.7.3.2.4. By Route of Administration 16.7.3.2.5. By Distribution Channel 16.7.4. Italy Market 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Drug Class 16.7.4.2.2. By Product 16.7.4.2.3. By Indication 16.7.4.2.4. By Route of Administration 16.7.4.2.5. By Distribution Channel 16.7.5. BENELUX Market 16.7.5.1. Introduction 16.7.5.2. Market Analysis and Forecast by Market Taxonomy 16.7.5.2.1. By Drug Class 16.7.5.2.2. By Product 16.7.5.2.3. By Indication 16.7.5.2.4. By Route of Administration 16.7.5.2.5. By Distribution Channel 16.7.6. Nordic Countries Market 16.7.6.1. Introduction 16.7.6.2. Market Analysis and Forecast by Market Taxonomy 16.7.6.2.1. By Drug Class 16.7.6.2.2. By Product 16.7.6.2.3. By Indication 16.7.6.2.4. By Route of Administration 16.7.6.2.5. By Distribution Channel 16.7.7. United kingdom Market 16.7.7.1. Introduction 16.7.7.2. Market Analysis and Forecast by Market Taxonomy 16.7.7.2.1. By Drug Class 16.7.7.2.2. By Product 16.7.7.2.3. By Indication 16.7.7.2.4. By Route of Administration 16.7.7.2.5. By Distribution Channel 17. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1.1. Poland 17.3.1.1.2. Hungary 17.3.1.1.3. Romania 17.3.1.1.4. Czech Republic 17.3.1.1.5. Rest of Eastern Europe 17.3.2. By Drug Class 17.3.3. By Product 17.3.4. By Indication 17.3.5. By Route of Administration 17.3.6. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Product 17.4.4. By Indication 17.4.5. By Route of Administration 17.4.6. By Distribution Channel 17.5. Market Trends 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. Poland Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Drug Class 17.7.1.2.2. By Product 17.7.1.2.3. By Indication 17.7.1.2.4. By Route of Administration 17.7.1.2.5. By Distribution Channel 17.7.2. Hungary Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Drug Class 17.7.2.2.2. By Product 17.7.2.2.3. By Indication 17.7.2.2.4. By Route of Administration 17.7.2.2.5. By Distribution Channel 17.7.3. Romania Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Drug Class 17.7.3.2.2. By Product 17.7.3.2.3. By Indication 17.7.3.2.4. By Route of Administration 17.7.3.2.5. By Distribution Channel 17.7.4. Czech Republic Market 17.7.4.1. Introduction 17.7.4.2. Market Analysis and Forecast by Market Taxonomy 17.7.4.2.1. By Drug Class 17.7.4.2.2. By Product 17.7.4.2.3. By Indication 17.7.4.2.4. By Route of Administration 17.7.4.2.5. By Distribution Channel 18. South Asia & Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. I India 18.3.1.2. Indonesia 18.3.1.3. Thailand 18.3.1.4. Philippines 18.3.1.5. Malaysia 18.3.1.6. Vietnam 18.3.1.7. Rest of South Asia 18.3.1.8. Australia & New Zealand 18.3.2. By Drug Class 18.3.3. By Product 18.3.4. By Indication 18.3.5. By Route of Administration 18.3.6. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Product 18.4.4. By Indication 18.4.5. By Route of Administration 18.4.6. By Distribution Channel 18.5. Market Trends 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. India Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Drug Class 18.7.1.2.2. By Product 18.7.1.2.3. By Indication 18.7.1.2.4. By Route of Administration 18.7.1.2.5. By Distribution Channel 18.7.2. Indonesia Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Drug Class 18.7.2.2.2. By Product 18.7.2.2.3. By Indication 18.7.2.2.4. By Route of Administration 18.7.2.2.5. By Distribution Channel 18.7.3. Thailand Market 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Drug Class 18.7.3.2.2. By Product 18.7.3.2.3. By Indication 18.7.3.2.4. By Route of Administration 18.7.3.2.5. By Distribution Channel 18.7.4. Philippines Market 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Drug Class 18.7.4.2.2. By Product 18.7.4.2.3. By Indication 18.7.4.2.4. By Route of Administration 18.7.4.2.5. By Distribution Channel 18.7.5. Malaysia Market 18.7.5.1. Introduction 18.7.5.2. Market Analysis and Forecast by Market Taxonomy 18.7.5.2.1. By Drug Class 18.7.5.2.2. By Product 18.7.5.2.3. By Indication 18.7.5.2.4. By Route of Administration 18.7.5.2.5. By Distribution Channel 18.7.6. Vietnam Market 18.7.6.1. Introduction 18.7.6.2. Market Analysis and Forecast by Market Taxonomy 18.7.6.2.1. By Drug Class 18.7.6.2.2. By Product 18.7.6.2.3. By Indication 18.7.6.2.4. By Route of Administration 18.7.6.2.5. By Distribution Channel 18.7.7. Australia & New Zealand Market 18.7.7.1. Introduction 18.7.7.2. Market Analysis and Forecast by Market Taxonomy 18.7.7.2.1. By Drug Class 18.7.7.2.2. By Product 18.7.7.2.3. By Indication 18.7.7.2.4. By Route of Administration 18.7.7.2.5. By Distribution Channel 19. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. Japan 19.3.1.2. China 19.3.1.3. South Korea 19.3.2. By Drug Class 19.3.3. By Product 19.3.4. By Indication 19.3.5. By Route of Administration 19.3.6. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Class 19.4.3. By Product 19.4.4. By Indication 19.4.5. By Route of Administration 19.4.6. By Distribution Channel 19.5. Market Trends 19.6. Drivers and Restraints - Impact Analysis 19.7. Country Level Analysis & Forecast 19.7.1. Japan Market 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Drug Class 19.7.1.2.2. By Product 19.7.1.2.3. By Indication 19.7.1.2.4. By Route of Administration 19.7.1.2.5. By Distribution Channel 19.7.2. China Market 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Drug Class 19.7.2.2.2. By Product 19.7.2.2.3. By Indication 19.7.2.2.4. By Route of Administration 19.7.2.2.5. By Distribution Channel 19.7.3. South Korea Market 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Drug Class 19.7.3.2.2. By Product 19.7.3.2.3. By Indication 19.7.3.2.4. By Route of Administration 19.7.3.2.5. By Distribution Channel 20. Central Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Drug Class 20.3.2. By Product 20.3.3. By Indication 20.3.4. By Route of Administration 20.3.5. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Drug Class 20.4.2. By Product 20.4.3. By Indication 20.4.4. By Route of Administration 20.4.5. By Distribution Channel 20.5. Market Trends 20.6. Drivers and Restraints - Impact Analysis 21. Russia & Belarus Market Analysis 2018 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Drug Class 21.3.2. By Product 21.3.3. By Indication 21.3.4. By Route of Administration 21.3.5. By Distribution Channel 21.4. Market Attractiveness Analysis 21.4.1. By Drug Class 21.4.2. By Product 21.4.3. By Indication 21.4.4. By Route of Administration 21.4.5. By Distribution Channel 21.5. Market Trends 21.6. Drivers and Restraints - Impact Analysis 22. Balkan & Baltic Countries Market Analysis 2018 to 2022 and Forecast 2023 to 2033 22.1. Introduction 22.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 22.3.1. By Drug Class 22.3.2. By Product 22.3.3. By Indication 22.3.4. By Route of Administration 22.3.5. By Distribution Channel 22.4. Market Attractiveness Analysis 22.4.1. By Drug Class 22.4.2. By Product 22.4.3. By Indication 22.4.4. By Route of Administration 22.4.5. By Distribution Channel 22.5. Market Trends 22.6. Drivers and Restraints - Impact Analysis 23. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033 23.1. Introduction 23.2. Historical Market Size (US$ Million) Analysis By Market Taxonomy, 2018 to 2022 23.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 23.3.1. By Country 23.3.1.1. GCC Countries 23.3.1.2. Kingdom of Saudi Arabia 23.3.1.3. Türkiye 23.3.1.4. Northern Africa 23.3.1.5. South Africa 23.3.1.6. Israel 23.3.2. By Drug Class 23.3.3. By Product 23.3.4. By Indication 23.3.5. By Route of Administration 23.3.6. By Distribution Channel 23.4. Market Attractiveness Analysis 23.4.1. By Country 23.4.2. By Drug Class 23.4.3. By Product 23.4.4. By Indication 23.4.5. By Route of Administration 23.4.6. By Distribution Channel 23.5. Market Trends 23.6. Drivers and Restraints - Impact Analysis 23.7. Country Level Analysis & Forecast 23.7.1. GCC Countries Market 23.7.1.1. Introduction 23.7.1.2. Market Analysis and Forecast by Market Taxonomy 23.7.1.2.1. By Drug Class 23.7.1.2.2. By Product 23.7.1.2.3. By Indication 23.7.1.2.4. By Route of Administration 23.7.1.2.5. By Distribution Channel 23.7.2. Kingdom of Saudi Arabia Market 23.7.2.1. Introduction 23.7.2.2. Market Analysis and Forecast by Market Taxonomy 23.7.2.2.1. By Drug Class 23.7.2.2.2. By Product 23.7.2.2.3. By Indication 23.7.2.2.4. By Route of Administration 23.7.2.2.5. By Distribution Channel 23.7.3. Türkiye Market 23.7.3.1. Introduction 23.7.3.2. Market Analysis and Forecast by Market Taxonomy 23.7.3.2.1. By Drug Class 23.7.3.2.2. By Product 23.7.3.2.3. By Indication 23.7.3.2.4. By Route of Administration 23.7.3.2.5. By Distribution Channel 23.7.4. Northern Africa Market 23.7.4.1. Introduction 23.7.4.2. Market Analysis and Forecast by Market Taxonomy 23.7.4.2.1. By Drug Class 23.7.4.2.2. By Product 23.7.4.2.3. By Indication 23.7.4.2.4. By Route of Administration 23.7.4.2.5. By Distribution Channel 23.7.5. South Africa Market 23.7.5.1. Introduction 23.7.5.2. Market Analysis and Forecast by Market Taxonomy 23.7.5.2.1. By Drug Class 23.7.5.2.2. By Product 23.7.5.2.3. By Indication 23.7.5.2.4. By Route of Administration 23.7.5.2.5. By Distribution Channel 23.7.6. Israel Market 23.7.6.1. Introduction 23.7.6.2. Market Analysis and Forecast by Market Taxonomy 23.7.6.2.1. By Drug Class 23.7.6.2.2. By Product 23.7.6.2.3. By Indication 23.7.6.2.4. By Route of Administration 23.7.6.2.5. By Distribution Channel 24. Market Structure Analysis 24.1. Market Analysis by Tier of Companies 24.2. Market Share Analysis of Top Players (%), 2020-2033 24.3. Market Share Analysis, 2022 24.4. Brand Share Analysis of Acetaminophen Market, 2022 25. Competition Analysis 25.1. Competition Dashboard 25.2. Competition Benchmarking 25.3. Key Development Analysis 25.4. Branding and Promotional Strategies 25.5. Competition Deep Dive 25.5.1. AbbVie Inc. (Allergan plc) 25.5.1.1. Overview 25.5.1.2. Product Portfolio 25.5.1.3. Sales Footprint 25.5.1.4. Key Financials 25.5.1.5. Key Developments 25.5.1.6. Strategy Overview 25.5.1.7. SWOT Analysis 25.5.2. Bristol Myers Squibb Co. 25.5.2.1. Overview 25.5.2.2. Product Portfolio 25.5.2.3. Sales Footprint 25.5.2.4. Key Financials 25.5.2.5. Key Developments 25.5.2.6. Strategy Overview 25.5.2.7. SWOT Analysis 25.5.3. Sanofi S.A. 25.5.3.1. Overview 25.5.3.2. Product Portfolio 25.5.3.3. Sales Footprint 25.5.3.4. Key Financials 25.5.3.5. Key Developments 25.5.3.6. Strategy Overview 25.5.3.7. SWOT Analysis 25.5.4. Boehringer Ingelheim International GmbH 25.5.4.1. Overview 25.5.4.2. Product Portfolio 25.5.4.3. Sales Footprint 25.5.4.4. Key Financials 25.5.4.5. Key Developments 25.5.4.6. Strategy Overview 25.5.4.7. SWOT Analysis 25.5.5. Pfizer Inc. 25.5.5.1. Overview 25.5.5.2. Product Portfolio 25.5.5.3. Sales Footprint 25.5.5.4. Key Financials 25.5.5.5. Key Developments 25.5.5.6. Strategy Overview 25.5.5.7. SWOT Analysis 25.5.6. Zydus Lifesciences Ltd. (Cadila Pharmaceuticals) 25.5.6.1. Overview 25.5.6.2. Product Portfolio 25.5.6.3. Sales Footprint 25.5.6.4. Key Financials 25.5.6.5. Key Developments 25.5.6.6. Strategy Overview 25.5.6.7. SWOT Analysis 25.5.7. GSK plc. 25.5.7.1. Overview 25.5.7.2. Product Portfolio 25.5.7.3. Sales Footprint 25.5.7.4. Key Financials 25.5.7.5. Key Developments 25.5.7.6. Strategy Overview 25.5.7.7. SWOT Analysis 25.5.8. Abbott Laboratories, Inc. 25.5.8.1. Overview 25.5.8.2. Product Portfolio 25.5.8.3. Sales Footprint 25.5.8.4. Key Financials 25.5.8.5. Key Developments 25.5.8.6. Strategy Overview 25.5.8.7. SWOT Analysis 25.5.9. Novartis AG 25.5.9.1. Overview 25.5.9.2. Product Portfolio 25.5.9.3. Sales Footprint 25.5.9.4. Key Financials 25.5.9.5. Key Developments 25.5.9.6. Strategy Overview 25.5.9.7. SWOT Analysis 25.5.10. Johnson & Johnson (Janssen Pharmaceuticals, Inc.) 25.5.10.1. Overview 25.5.10.2. Product Portfolio 25.5.10.3. Sales Footprint 25.5.10.4. Key Financials 25.5.10.5. Key Developments 25.5.10.6. Strategy Overview 25.5.10.7. SWOT Analysis 25.5.11. Sun Pharmaceutical Industries Ltd. 25.5.11.1. Overview 25.5.11.2. Product Portfolio 25.5.11.3. Sales Footprint 25.5.11.4. Key Financials 25.5.11.5. Key Developments 25.5.11.6. Strategy Overview 25.5.11.7. SWOT Analysis 25.5.12. Teva Pharmaceuticals Ltd. 25.5.12.1. Overview 25.5.12.2. Product Portfolio 25.5.12.3. Sales Footprint 25.5.12.4. Key Financials 25.5.12.5. Key Developments 25.5.12.6. Strategy Overview 25.5.12.7. SWOT Analysis 25.5.13. Mallinckrodt Pharmaceuticals 25.5.13.1. Overview 25.5.13.2. Product Portfolio 25.5.13.3. Sales Footprint 25.5.13.4. Key Financials 25.5.13.5. Key Developments 25.5.13.6. Strategy Overview 25.5.13.7. SWOT Analysis 25.5.14. Endo Pharmaceuticals Inc. 25.5.14.1. Overview 25.5.14.2. Product Portfolio 25.5.14.3. Sales Footprint 25.5.14.4. Key Financials 25.5.14.5. Key Developments 25.5.14.6. Strategy Overview 25.5.14.7. SWOT Analysis 25.5.15. Bayer AG 25.5.15.1. Overview 25.5.15.2. Product Portfolio 25.5.15.3. Sales Footprint 25.5.15.4. Key Financials 25.5.15.5. Key Developments 25.5.15.6. Strategy Overview 25.5.15.7. SWOT Analysis 25.5.16. F. Hoffmann-La Roche Ltd. 25.5.16.1. Overview 25.5.16.2. Product Portfolio 25.5.16.3. Sales Footprint 25.5.16.4. Key Financials 25.5.16.5. Key Developments 25.5.16.6. Strategy Overview 25.5.16.7. SWOT Analysis 25.5.17. Procter & Gamble 25.5.17.1. Overview 25.5.17.2. Product Portfolio 25.5.17.3. Sales Footprint 25.5.17.4. Key Financials 25.5.17.5. Key Developments 25.5.17.6. Strategy Overview 25.5.17.7. SWOT Analysis 25.5.18. AstraZeneca 25.5.18.1. Overview 25.5.18.2. Product Portfolio 25.5.18.3. Sales Footprint 25.5.18.4. Key Financials 25.5.18.5. Key Developments 25.5.18.6. Strategy Overview 25.5.18.7. SWOT Analysis 25.5.19. Cardinal Health 25.5.19.1. Overview 25.5.19.2. Product Portfolio 25.5.19.3. Sales Footprint 25.5.19.4. Key Financials 25.5.19.5. Key Developments 25.5.19.6. Strategy Overview 25.5.19.7. SWOT Analysis 25.5.20. Perrigo Company Plc. 25.5.20.1. Overview 25.5.20.2. Product Portfolio 25.5.20.3. Sales Footprint 25.5.20.4. Key Financials 25.5.20.5. Key Developments 25.5.20.6. Strategy Overview 25.5.20.7. SWOT Analysis 25.5.21. Bausch Health Companies Inc. 25.5.21.1. Overview 25.5.21.2. Product Portfolio 25.5.21.3. Sales Footprint 25.5.21.4. Key Financials 25.5.21.5. Key Developments 25.5.21.6. Strategy Overview 25.5.21.7. SWOT Analysis 25.5.22. Viatris 25.5.22.1. Overview 25.5.22.2. Product Portfolio 25.5.22.3. Sales Footprint 25.5.22.4. Key Financials 25.5.22.5. Key Developments 25.5.22.6. Strategy Overview 25.5.22.7. SWOT Analysis 25.5.23. AMillioneal Pharmaceuticals 25.5.23.1. Overview 25.5.23.2. Product Portfolio 25.5.23.3. Sales Footprint 25.5.23.4. Key Financials 25.5.23.5. Key Developments 25.5.23.6. Strategy Overview 25.5.23.7. SWOT Analysis 25.5.24. Purdue Pharmaceuticals L.P. 25.5.24.1. Overview 25.5.24.2. Product Portfolio 25.5.24.3. Sales Footprint 25.5.24.4. Key Financials 25.5.24.5. Key Developments 25.5.24.6. Strategy Overview 25.5.24.7. SWOT Analysis 26. Assumptions and Acronyms Used 27. Research Methodology
Explore Healthcare Insights
View Reports
Painkillers Market
